Deficiency of Adenosine Deaminase 2 (DADA2), an Inherited Cause of Polyarteritis Nodosa and a Mimic of Other Systemic Rheumatologic Disorders

作者：Hashem Hasan; Kelly Susan J; Ganson Nancy J; Hershfield Michael S^*

来源：Current Rheumatology Reports, 2017, 19(11): 70.

DOI：10.1007/s11926-017-0699-8

• Monogenic autoinflammatory disorder
• CECR1
• Vasculopathy
• Polyarteritis nodosa
• Stroke
• Immune deficiency
• Pure red cell aplasia
• Macrophage polarization
• TNF inhibitor
• Hematopoietic stemcell transplant
• Adenosine deaminase
• Whole-exome sequencing

Purpose of Review A new autoinflammatory disease, deficiency of adenosine deaminase 2 (DADA2), caused by mutations in the CECR1 gene, was first reported in 2014. This review aims to update progress in defining, treating, and understanding this multi-faceted disorder.
Recent Findings DADA2 was first described in patients with systemic inflammation, mild immune deficiency, and vasculopathy manifested as recurrent stroke or polyarteritis nodosa (PAN). More than 125 patients have now been reported, and the phenotype has expanded to include children and adults presenting primarily with pure red cell aplasia (PRCA), or with antibody deficiency. Age of onset and clinical severity vary widely, even among related patients, and are not clearly related to CECR1 genotype. Inflammatory features often respond to anti-TNF agents, but marrow failure and severe immune deficiency may require hematopoietic stem cell transplantation.
Summary ADA2 is expressed and secreted by monocytes and macrophages, but its biological function and the pathogenesis of DADA2 are uncertain and will remain an important area of research. Pre-clinical investigation of ADA2 replacement therapy and CECR1-directed gene therapy are warranted, but complicated by the absence of a suitable animal model.

• 出版日期2017-11